Terns Pharmaceuticals, Inc. (TERN)
Automate Your Wheel Strategy on TERN
With Tiblio's Option Bot, you can configure your own wheel strategy including TERN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TERN
- Rev/Share 0.0
- Book/Share 3.3331
- PB 11.0528
- Debt/Equity 0.0037
- CurrentRatio 24.6982
- ROIC -0.3435
- MktCap 3318462394.0
- FreeCF/Share -0.812
- PFCF -44.6276
- PE -36.7718
- Debt/Assets 0.0035
- DivYield 0
- ROE -0.2735
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | TERN | H.C. Wainwright | Neutral | Buy | -- | $20 | Nov. 4, 2025 |
| Upgrade | TERN | William Blair | Market Perform | Outperform | -- | -- | Nov. 3, 2025 |
| Initiation | TERN | Truist | -- | Buy | -- | $20 | Oct. 15, 2025 |
| Initiation | TERN | Barclays | -- | Overweight | -- | $15 | Sept. 17, 2025 |
| Resumed | TERN | H.C. Wainwright | -- | Neutral | -- | -- | Sept. 4, 2025 |
| Initiation | TERN | William Blair | -- | Market Perform | -- | -- | Feb. 28, 2025 |
News
Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again
Published: December 09, 2025 by: Seeking Alpha
Sentiment: Positive
Terns Pharmaceuticals, Inc. stock has surged 770% YTD, driven by strong TERN-701 data in chronic myeloid leukemia, or CML, the latest outstanding data set shared yesterday. TERN-701 demonstrated superior major molecular response rates versus Novartis' Scemblix, with robust safety and efficacy in heavily pre-treated CML patients. Management is prioritizing TERN-701, raising $400M for pivotal studies, with Phase 3 initiation and regulatory milestones as key upcoming catalysts.
Read More
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
Published: December 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses > 320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today …
Read More
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors
Published: December 03, 2025 by: The Motley Fool
Sentiment: Positive
New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable assets under management (AUM).
Read More
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8 th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in participants with previously treated chronic myeloid leukemia (CML) has been selected for oral presentation on December 8, 2025 at …
Read More
Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?
Published: October 22, 2025 by: Benzinga
Sentiment: Negative
On Tuesday, Terns Pharmaceuticals Inc. (NASDAQ:TERN) shared topline 12-week results from its FALCON Phase 2 trial of TERN-601.
Read More
Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Terns Pharmaceuticals, Inc. (NASDAQ:TERN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:00 AM EDT Company Participants Amy Burroughs - CEO & Director Scott Harris - Chief Development Officer Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy All right. Thanks, everybody, for joining us.
Read More
Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts
Published: July 11, 2025 by: Seeking Alpha
Sentiment: Positive
Terns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of best-in-class potential in CML, with encouraging molecular response and safety data versus Novartis' Scemblix. TERN-601's oral GLP-1 candidate demonstrated promising weight loss and tolerability, targeting a massive obesity market with room for differentiated entrants.
Read More
3 Penny Stocks Wall Street Sees With 243% Upside
Published: June 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
Read More
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations
Read More
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Terns Pharmaceuticals (TERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Terns Pharmaceuticals, Inc. (TERN)
- IPO Date 2021-02-05
- Website https://www.ternspharma.com
- Industry Biotechnology
- CEO Amy L. Burroughs
- Employees 59